The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.a

Pulmonary embolism - Venous thrombosis/thromboembolism

Publications

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW Jr, Langholff W, Sandborn WJ

Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.

Inflammatory bowel diseases. 2018;24(3):490-501

Eklund KK, Peltomaa R, Leirisalo-Repo M

Occurrence of pulmonary thromboembolism during infliximab therapy.

Clinical and experimental rheumatology. 2003;21(5):679